Showing 6021-6030 of 9769 results for "".
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s
- NanoViricides: Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Modelhttps://practicaldermatology.com/news/nanoviricides-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model/2458963/NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the la
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- New Officers Assume Roles with the American Academy of Dermatologyhttps://practicaldermatology.com/news/new-officers-assume-roles-with-the-american-academy-of-dermatology/2458976/Mark Lebwohl, MD, FAAD, a dermatologist in New York City, took office as president of the American Academy of Dermatology (AAD). Timothy G. Berger, MD, FAAD, a dermatologist in San Francisco, also assumed his position as vice president of the AAD. Drs. Lebwohl and Berger assumed office at the con
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- MDRejuvena Launches Novel Product Line Focused on Skin Healthhttps://practicaldermatology.com/news/mdrejuvena-launches-novel-product-line-focused-on-skin-health/2458978/MDRejuvena, Inc. launched its novel, proprietary product line at the American Academy of Dermatology Meeting in San Francisco. MDRejuvena's product line, designed to rejuvenate, enhance, and maintain skin health, incorporates Phytochromatic MDT Complex, a proprietary, patented, plant-derived
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne